- Home
- MYGN vs BCX Comparison
MYGN vs BCX Comparison
Compare MYGN & BCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- BCX
- Stock Information
- Founded
- MYGN 1991
- BCX 2011
- Country
- MYGN United States
- BCX United States
- Employees
- MYGN N/A
- BCX N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- BCX Finance/Investors Services
- Sector
- MYGN Health Care
- BCX Finance
- Exchange
- MYGN Nasdaq
- BCX Nasdaq
- Market Cap
- MYGN 744.7M
- BCX 674.0M
- IPO Year
- MYGN 1995
- BCX N/A
- Fundamental
- Price
- MYGN $7.29
- BCX $8.84
- Analyst Decision
- MYGN Hold
- BCX
- Analyst Count
- MYGN 16
- BCX 0
- Target Price
- MYGN $20.17
- BCX N/A
- AVG Volume (30 Days)
- MYGN 1.2M
- BCX 370.6K
- Earning Date
- MYGN 05-06-2025
- BCX 01-01-0001
- Dividend Yield
- MYGN N/A
- BCX 6.99%
- EPS Growth
- MYGN N/A
- BCX N/A
- EPS
- MYGN N/A
- BCX N/A
- Revenue
- MYGN $837,600,000.00
- BCX N/A
- Revenue This Year
- MYGN $2.99
- BCX N/A
- Revenue Next Year
- MYGN $8.36
- BCX N/A
- P/E Ratio
- MYGN N/A
- BCX N/A
- Revenue Growth
- MYGN 11.21
- BCX N/A
- 52 Week Low
- MYGN $7.35
- BCX $8.25
- 52 Week High
- MYGN $29.30
- BCX $9.90
- Technical
- Relative Strength Index (RSI)
- MYGN 25.95
- BCX 50.64
- Support Level
- MYGN $7.69
- BCX $8.57
- Resistance Level
- MYGN $8.27
- BCX $8.86
- Average True Range (ATR)
- MYGN 0.56
- BCX 0.29
- MACD
- MYGN 0.02
- BCX 0.03
- Stochastic Oscillator
- MYGN 1.02
- BCX 73.44
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About BCX BlackRock Resources of Beneficial Interest
BlackRock Resources & Commodities Strategy Trust operates as an investment trust. Its investment objective is to seek high current income and current gains, with a secondary objective of capital appreciation. The company invests at least 80% of its total assets in equity securities issued by commodity or natural resources companies, derivatives with exposure to commodity or natural resources companies or investments in securities and derivatives linked to the underlying price movement of commodities or natural resources.